Status:
COMPLETED
Impact of COVID-19 Vaccination on Serum 25-hydroxyvitamin D Level
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Acne Vulgaris
Vitamin D Deficiency
Eligibility:
All Genders
20-64 years
Brief Summary
Vitamin D plays a pivotal but still not well understood role in the immune response to coronavirus disease (COVID-19) infection and vaccination. Many studies also showed a high negative correlation be...
Detailed Description
Vitamin D is known to be related with calcium and bone metabolism. Recently, vitamin D has been shown to play an important role in innate and acquired immunity, cytokine release, inflammatory response...
Eligibility Criteria
Inclusion
- Age of ≥ 20 years and \< 65 years
- Diagnosis of acne vulgaris
- The one will receive the third dose of COVID-19 vaccine
- Signing informed consent
Exclusion
- History of COVID-19 infection
- Currently taking vitamin-D, steroid, or any drugs for acne vulgaris.
- Coagulopathy
- Having any chronic inflammation disease, immunity-related disease, diabetes, mellitus, kidney disease, or liver disease.
- Have acute inflammation disease, for example, upper respiratory infection or urinary tract infection
- Pregnancy or lactation
- History of cancer or any major systematic disease
Key Trial Info
Start Date :
May 25 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 29 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05398939
Start Date
May 25 2022
End Date
November 29 2022
Last Update
April 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Dermatology, National Taiwan University Hospital
Taipei, Taiwan